1. Scrip

From Big Pharma To Biotech: Rare Disease R&D Blossoms As French Biotech Pipelines Mature

 
• By Ayisha Sharma

French Biotech In Focus: While R&D at French biopharma firms in general reflects worldwide trends for oncology and neurology, rare diseases are coming more to the fore, backed by the country’s world-class academic institutions and US FDA recognition.    

France Biotech Focus
The Emerging Rare Diseases Pipeline Could Help Diversify France's Biotech Offering • Source: Shutterstock

Rare diseases are becoming increasingly important to French biotech firms, as the sector matures with the help of a government push to improve the ecosystem in the country.

Orphan drug research could help carve a new niche for a country known mainly for its development of ophthalmology drugs and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip